Select a date that works for you, and click on the “Proceed” button at the bottom of the page to complete a pre-registration survey and enroll in your date. Participants who enroll more than 2 weeks in advance will receive a headset in the mail (with a prepaid return envelope). Otherwise, participants can use their computers’ speakers and type any questions they may have during the course. CE Certificates and Statements of Credit will be available immediately online after participants successfully complete the post-test and evaluation.
Multiple sclerosis (MS) is a costly disease in terms of its effects on patients’ quality of life and its financial cost to society. The introduction of treatments that are designed to change the natural disease course has focused attention on the economic burden of MS. Balancing cost-effective treatment with current guidelines and optimal therapy is a challenge to physicians and pharmacists practicing in the managed care setting. In order to be effective in their roles, managed care physicians and pharmacists and specialty pharmacists need a sense of the economic value of MS drug therapies for formulary selection and/or placement and optimizing patient care. This web-based classroom activity, which focuses on evaluating the clinical course and pathology of MS, is 1 in a series of 3 activities that will present perspectives from an MS neurologist, medical director, and pharmacy director on how to translate this wealth of information into clinical practice to improve patient and pharmacoeconomic outcomes.
This activity is designed for managed care physicians and pharmacists. No prerequisites required.
The Albert Einstein College of Medicine and University of Tennessee College of Pharmacy take responsibility for the content, quality, and scientific integrity of this CPE activity. Upon the conclusion of this activity, the participant should be able to:
- Evaluate data concerning the effects of MS therapies on neuronal preservation and slowing disease progression when initiated early within the disease course.
- Compare the safety and efficacy of emerging therapies to currently available disease-modifying agents for reducing disability and relapse rate in MS.
Sheldon J. Rich, RPh, PhD (Course Director)
President – SJR Associates, LLC
Palm Beach Gardens, Florida
Adjunct Clinical Assistant Professor
University of Michigan
Adjunct Assistant Professor
Wayne State University
Gary Birnbaum, MD
Multiple Sclerosis Treatment and Research Center
Golden Valley, Minnesota
Clinical Professor of Neurology
University of Minnesota School of Medicine
Rene Elkin, MD (Reviewer)
Bronx-Lebanon Hospital Center
The Saul R. Korey Department of Neurology
Albert Einstein College of Medicinev
Maria Lopes, MD, MS
Chief Medical Officer
Cresskill, New Jersey
Patricia Gellasch, MSN, APN-C (Medical Director)
Visiting Clinical Associate in the The College of Nursing
Rutgers, The State University of NJ
New Brunswick, NJ
Participating Faculty Disclosures
Sheldon J. Rich, RPh, PhD, reports serving as an advisory board moderator for Astellas Pharma US, Inc, Gilead Sciences, GlaxoSmithKline, and Teva Neuroscience; serving as an advisory board participant for Acorda Therapeutics; and serving as an expert witness for Rutledge, Manion, Rabaut, Terry & Thomas.
Gary Birnbaum, MD, reports receiving grants/research support from Biogen IDEC; serving as a consultant for Serono and Teva Neuroscience; and having other relationships with Pfizer Inc, Serono, and Teva Neuroscience.
Dr Elkin reports serving as a consultant for Bayer, Biogen IDEC, Pfizer Inc, and Teva; holding stock in Pfizer Inc; and serving on the speakers’ bureau for Bayer, Biogen IDEC, and Teva.
Maria Lopes, MD, MS, reports serving as an ad board member for Biogen IDEC (planned for November 17 and 18).
Patricia Gellasch, MSN, APN-C, reports having no relevant financial or advisory relationships with corporate organizations related to this activity.
Albert Einstein College of Medicine, CCME staff, has no conflicts of interest with commercial interests related directly or indirectly to this educational activity. The staff of CCME of Albert Einstein College of Medicine have no disclosures to report with commercial interests other than the following:
Steven Jay Feld, or a member of his household own securities in:
Bioheart, Inc., Chelsea Therapeutics, Inc. and Pharmacopeia, Inc.
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through joint sponsorship of Albert Einstein College of Medicine of Yeshiva University, Montefiore Medical Center, The University of Tennessee College of Pharmacy, and ASiM. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
The University of Tennessee College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education to provide continuing education for pharmacists.
Albert Einstein College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This knowledge-based activity is sponsored by The University of Tennessee College of Pharmacy who is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Successful completion of this knowledge-based educational activity will provide 1.0 contact hours credit (0.10 CEUs). A statement of CE credit will be mailed within 4 weeks following successful completion of the educational activity. Successful completion includes attending the session, signing the attendance sheet, and completion of the educational activity evaluation form. ACPE Program #0064-0000-11-209-L01-P.
The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical, product, or device company. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present.
The Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
It is the policy of The University of Tennessee College of Pharmacy that the faculty and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during the presentation(s). Detailed disclosures will be made in the course materials.
The Albert Einstein College of Medicine and The University of Tennessee College of Pharmacy fully complies with the legal requirements of the ADA and the rules and regulations thereof. Please notify us if you have any special needs.
The opinions expressed herein are those of the authors and do not necessarily represent the views of the Albert Einstein College of Medicine, the National Association of Managed Care Physicians, or ASiM. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.
A participant, sponsor, faculty member, or other individual wanting to file a grievance with respect to any aspect of an activity sponsored or cosponsored by The University of Tennessee College of Pharmacy may contact the Associate Dean for Continuing Education in writing at email@example.com. The grievance will be reviewed and a response will be returned within 45 days of receiving the written statement. If not satisfied, an appeal to the Dean of the College of Pharmacy can be made for a second level review.
There is no fee for this educational activity.